231 related articles for article (PubMed ID: 21331930)
41. Clinical impact of 18F-FDG-PET in the suspicion of recurrent colorectal cancer based on asymptomatically elevated serum level of carcinoembryonic antigen (CEA) in Taiwan.
Shen YY; Liang JA; Chen YK; Tsai CY; Kao CH
Hepatogastroenterology; 2006; 53(69):348-50. PubMed ID: 16795969
[TBL] [Abstract][Full Text] [Related]
42. Use of laxative-augmented contrast medium in the evaluation of colorectal foci at FDG PET.
Chen YK; Chen JH; Tsui CC; Chou HH; Cheng RH; Chiu JS
Radiology; 2011 May; 259(2):525-33. PubMed ID: 21406631
[TBL] [Abstract][Full Text] [Related]
43. [18F]FDG PET/CT imaging of colorectal cancer: a pictorial review.
Chowdhury FU; Shah N; Scarsbrook AF; Bradley KM
Postgrad Med J; 2010 Mar; 86(1013):174-82. PubMed ID: 20237012
[TBL] [Abstract][Full Text] [Related]
44. [Clinical use of 18F-FDG PET/CT in colorectal carcinoma].
Németh Z; Boér K; Kásler M; Borbély K
Orv Hetil; 2013 Sep; 154(37):1447-53. PubMed ID: 24016751
[TBL] [Abstract][Full Text] [Related]
45. [18F]Fluorodeoxyglucose PET/Computed Tomography in Gastrointestinal Malignancies.
Donswijk ML; Hess S; Mulders T; Lam MG
PET Clin; 2014 Oct; 9(4):421-41, v-vi. PubMed ID: 26050945
[TBL] [Abstract][Full Text] [Related]
46. Detection of primary and recurrent lung cancer by means of F-18 fluorodeoxyglucose positron emission tomography (FDG PET).
Duhaylongsod FG; Lowe VJ; Patz EF; Vaughn AL; Coleman RE; Wolfe WG
J Thorac Cardiovasc Surg; 1995 Jul; 110(1):130-9; discussion 139-40. PubMed ID: 7609536
[TBL] [Abstract][Full Text] [Related]
47. Significance of 18F-fluorodeoxyglucose positron-emission tomography/computed tomography for the postoperative surveillance of advanced renal cell carcinoma.
Park JW; Jo MK; Lee HM
BJU Int; 2009 Mar; 103(5):615-9. PubMed ID: 19007371
[TBL] [Abstract][Full Text] [Related]
48. Role of 2-[18F] fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in the post-therapy surveillance of breast cancer.
Chang HT; Hu C; Chiu YL; Peng NJ; Liu RS
PLoS One; 2014; 9(12):e115127. PubMed ID: 25517451
[TBL] [Abstract][Full Text] [Related]
49. The role of 18F-FDG PET in staging and early prediction of response to therapy of recurrent gastrointestinal stromal tumors.
Gayed I; Vu T; Iyer R; Johnson M; Macapinlac H; Swanston N; Podoloff D
J Nucl Med; 2004 Jan; 45(1):17-21. PubMed ID: 14734662
[TBL] [Abstract][Full Text] [Related]
50. Predictors of initial 18F-fluorodeoxyglucose-positron emission tomography indication among patients with colorectal cancer.
Zafar HM; Kramer S; Bonaccorsi D; Langlotz CP; Armstrong K
Nucl Med Commun; 2012 Jul; 33(7):739-46. PubMed ID: 22531828
[TBL] [Abstract][Full Text] [Related]
51. The role of 18F-FDG PET/CT in detecting colorectal cancer recurrence in patients with elevated CEA levels.
Ozkan E; Soydal C; Araz M; Kir KM; Ibis E
Nucl Med Commun; 2012 Apr; 33(4):395-402. PubMed ID: 22367859
[TBL] [Abstract][Full Text] [Related]
52. [F-18 fluorodeoxyglucose positron emission tomography in colorectal carcinoma].
Jörg L; Langsteger W
Wien Med Wochenschr; 2002; 152(11-12):276-9. PubMed ID: 12138655
[TBL] [Abstract][Full Text] [Related]
53. 18F-fluorodeoxyglucose positron emission tomography-computed tomography for suspected recurrent papillary thyroid cancer: early experience at Sunnybrook Health Sciences Centre.
Dahele M; Ung YC; Ehrlich L; Silverberg J; Balogh J; Wong CS
J Otolaryngol Head Neck Surg; 2008 Oct; 37(5):712-7. PubMed ID: 19128681
[TBL] [Abstract][Full Text] [Related]
54. [Influence of FDG-PET-CT on diagnostic and treatment of colorectal cancer].
Kolev N; Tonev A; Ignatov V; Ivanov G; Ivanov K
Khirurgiia (Sofiia); 2011; (3):55-61. PubMed ID: 23844462
[TBL] [Abstract][Full Text] [Related]
55. A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer.
Kauhanen SP; Komar G; Seppänen MP; Dean KI; Minn HR; Kajander SA; Rinta-Kiikka I; Alanen K; Borra RJ; Puolakkainen PA; Nuutila P; Ovaska JT
Ann Surg; 2009 Dec; 250(6):957-63. PubMed ID: 19687736
[TBL] [Abstract][Full Text] [Related]
56. Use of semiquantitative analysis in local recurrence of colorectal carcinoma with
Gedik GK; Yilmaz F
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2018; 37(6):366-372. PubMed ID: 30193775
[TBL] [Abstract][Full Text] [Related]
57. Optimal interpretation of FDG PET in the diagnosis, staging and management of pancreatic carcinoma.
Delbeke D; Rose DM; Chapman WC; Pinson CW; Wright JK; Beauchamp RD; Shyr Y; Leach SD
J Nucl Med; 1999 Nov; 40(11):1784-91. PubMed ID: 10565771
[TBL] [Abstract][Full Text] [Related]
58. Positron emission tomography with fluorodeoxyglucose for suspected head and neck tumor recurrence in the symptomatic patient.
Lonneux M; Lawson G; Ide C; Bausart R; Remacle M; Pauwels S
Laryngoscope; 2000 Sep; 110(9):1493-7. PubMed ID: 10983949
[TBL] [Abstract][Full Text] [Related]
59. FDG-PET improves the staging and selection of patients with recurrent colorectal cancer.
Lonneux M; Reffad AM; Detry R; Kartheuser A; Gigot JF; Pauwels S
Eur J Nucl Med Mol Imaging; 2002 Jul; 29(7):915-21. PubMed ID: 12111132
[TBL] [Abstract][Full Text] [Related]
60. ¹⁸F-Fluorodeoxyglucose positron emission tomography/computed tomography finds answers in cancer patients with increasing tumor markers and negative or equivocal conventional imaging modalities.
Salem SS; Shahin MA
Nucl Med Commun; 2012 Mar; 33(3):313-21. PubMed ID: 22237387
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
